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OBJECTIVES The aim of our study was to identify genetic causes of primary pulmonary hypertension
(PPH), to estimate the proportion of families with mutations in the BMPR2 (bone
morphogenetic protein receptor type 2) gene, and to examine whether genetic heterogeneity
might play a role.
BACKGROUND The BMPR2 mutations have been identified in a substantial portion of patients with familial
or sporadic PPH. However, the genetic cause of PPH remains unclear in at least 45% of
families.
METHODS We investigated 130 members of 10 families with at least 1 PPH patient, recruited without
selection for familial disease. Manifest PPH was documented in 21 individuals. An increase
in pulmonary artery systolic pressure (PASP) above 40 mm Hg during supine bicycle exercise
was found in 46 healthy individuals. Their PASP increased from 21.0  4.6 mm Hg at rest
to 54.0  9.8 mm Hg during exercise. In 51 relatives, PASP values were normal at rest and
during exercise, and 12 members were classified as status unknown.
RESULTS Two families showed a mutation in the BMPR2 gene. Three families with no BMBR2
mutation showed evidence for linkage to a more proximal location on chromosome 2q31
(odds ratio [OR] for linkage 1.1·106:1). This locus, designated PPH2, maps in-between the
markers D2S335 and D2S2314. We obtained significant support for heterogeneity in PPH
with an OR of 2.8·1011.
CONCLUSIONS We conclude that PPH may be a genetically heterogeneous disorder with at least two—and
possibly more—causative genes. (J Am Coll Cardiol 2003;41:2237–44) © 2003 by the
American College of Cardiology Foundation
Primary pulmonary hypertension (PPH) is a rare disease
characterized by increased resistance of precapillary pulmo-
nary arteries and a poor prognosis. Familial PPH was
initially mapped to a single locus on chromosome 2q31-32
(1–3). Recently, autosomal dominant germline mutations in
the bone morphogenetic protein receptor type 2 (BMPR2)
gene localized on chromosome 2q33 (PPH1-gene) have
been identified in approximately 55% of familial cases (4–6)
and in 25% of patients with negative family history (6,7).
However, the genetic cause remains unclear in almost half
the patients.
The BMPR2 gene is a ubiquitously expressed receptor for
secreted growth factors (bone morphogenetic proteins) and
a member of the transforming growth factor-beta (TGF-
beta) receptor family. Most of the identified BMPR2
sequence variants are truncating mutations, whereas the
majority of missense mutations have been shown to be
located in highly conserved domains, like the receptor
kinase domain (4–6). The BMPR2 expression level has
been shown to be reduced in the peripheral lung of patients
with and without a BMPR2 mutation (8). Rudarakanchana
et al. (9) reported that all recombinant constructs carrying a
BMPR2 mutation caused increased cell proliferation, a
process associated with the activation of the p38 protein.
The p38 protein is a Smad-independent member of the
TGF-beta–related signaling network. Hence, it is most
likely that mutations in BMPR2 can cause PPH.
Recently, we demonstrated that a predisposition to PPH
can be diagnosed at an early stage of disease using stress
Doppler echocardiography (SDE) (10). A pathological rise
of pulmonary artery systolic pressure (PASP) during supine
bicycle exercise was observed in family members who shared
the risk haplotype with the index patients. The micro-
satellite markers used in this previous study mapped to
chromosome 2q31-32. The BMPR2 gene was isolated from
the more distal band 2q33. Thus, an apparent discrepancy
exists between the mapping data obtained in these studies.
The aim of this investigation was to determine whether
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genetic heterogeneity might be an explanation for these
findings.
SUBJECTS AND METHODS
The family panel. Between January 1998 and January
2000, we prospectively investigated the families of 39 index
patients with PPH. All families (n  10) with more than
two potentially informative meioses were selected for link-
age analysis. Two of these families, family 965 and family
1490, have been described before as “family A and B,”
respectively (10). In all index patients the diagnosis of PPH
was confirmed by right heart catheterization or autopsy and
was made according to the criteria of the World Health
Organization (11). For decreased relatives, medical records
were reviewed when available, and the diagnosis of PPH
was based on the criteria used for index patients. Pulmonary
artery systolic pressure (PASP) was assessed at rest and
during supine bicycle exercise (ER900EL, ergoline, Bitz,
Germany) using SDE as described previously (10,12). In
subjects with abnormal PASP values, secondary causes have
been excluded on the basis of a cascade of clinical assess-
ments including lung function tests with body plethysmog-
raphy, carbon dioxide diffusing capacity, arterial blood gas
analysis, chest X-ray, and in some cases heart catheteriza-
tion. Left ventricular diastolic dysfunction was excluded by
Doppler echocardiography at rest. All family members with
possibly secondary reasons for an abnormal PASP such as
blood pressures exceeding 220/110 mm Hg during exercise
were classified as “status unknown” in the linkage analysis.
Right heart catheterization (RHC) was performed in all
index patients at rest and in 13 relatives who complained of
exercise-induced shortness of breath at rest and during
exercise.
The control group consisted of 60 subjects (36 female, 24
male, mean age 27  10 years, weight 66  12 kg, height
175  9 cm). Acute or chronic pulmonary or cardiac
diseases were ruled out in all subjects. The clinicians were
blinded to the results of genetic analysis. The Ethics
Committee of the Medical Faculty of the University of
Heidelberg approved the protocol of this study, and family
members and controls gave their written informed consent.
Mutation analysis. Blood samples were collected for ge-
netic analysis, and DNA was extracted from peripheral
blood using a standard salting-out procedure. The BMPR2
mutation screening was performed in all index patients.
The primer sequences used to amplify the gene fragments
by polymerase chain reaction (PCR) can be obtained from
the corresponding author. We performed cycle sequencing
with Big Dye terminators on an ABI 3700 sequencer
according to the manufacturer’s recommendations (M.P.,
W.N.). To confirm that no mutations had been missed
owing to low-grade mosaicism or sequencing artefacts, we
rescreened these 10 patients by denaturing high perfor-
mance liquid chematography (dHPLC) (Transgenomics
“WAVE” Nucleic Acid Fragment Analysis System) in a
second independent laboratory (R.K.). Each PCR product
was dHPLC-analyzed by using at least two different pro-
tocols per exon according to the manufacturer’s directions.
Microsatellite and linkage analysis. All families under-
went genotyping for microsatellite markers covering the
entire PPH candidate region (1): D2S222, D2S284,
D2S156, D2S335, CHRNA1, D2S2314, D2S389,
D2S309, and D2S307. Families 965, 1893, and 2135 were
also typed for the additional markers D2S2307, D2S2188,
D2S148, D2S364, D2S350, D2S2336, D2S324, D2S360,
D2S2193, D2S1384, D2S369, and D2S143. The primer
sequences were obtained from GDB (The Genomic Data-
base), and PCR was performed according to GDB recom-
mendations. We used CY5-labeled forward primers and
analyzed the genotypes on an ALF-Express automatic
sequencer.
The nine three-generation families were statistically an-
alyzed by the GENEHUNTER program (13). As family
965 was too large for analysis by GENEHUNTER, we used
the LINKAGE programs version 5.1 to calculate lod scores
(logarithm of the odds) for this extended four-generation
family (14). The standard markers were recoded to a three-,
four-, or five-allele system and analyzed by overlapping runs
of LINKMAP (5-point analyses) (family 965) or analyzed
without recoding by GENEHUNTER (all other families).
Carriers of PPH risk haplotypes were expected to show an
abnormal response to exercise, with the exception of a small
number of young individuals (age20) (10). In accord with
this, we calculated with 99% penetrance in adult individuals
and 80% penetrance in persons 20 years of age. We used
a rather conservative phenocopy rate of 20%. For individuals
with manifest PPH we calculated with a phenocopy rate of
0.0001% (misclassified individuals with a secondary form).
We used a disease allele frequency of 1 in 10,000. Inter-
marker distances were obtained from NCBI (National
Center for Biotechnology Information). The lod scores were
calculated at intervals of 0.5 cM and converted into
heterogeneity-corrected lod scores by applying the Admix-
ture test (15). At each map position the heterogeneity-
corrected lod score was maximized by optimizing the
proportion of linked families () in steps of 1%. Posterior
probabilities () were calculated by the formula:  
(·10Z1)/([·10Z1]  [1  ]·[10Z2]), where Z1 and Z2
represent the lod scores at locus 1 (BMPR2) and locus 2 (a
Abbreviations and Acronyms
AR  abnormal PASP response to exercise
BMPR2  bone morphogenetic protein receptor type 2
dHPLC  denaturing high performance liquid
chromatography
lod  logarithm of the odds for linkage
NR  normal PASP response to exercise
PASP  pulmonary artery systolic pressure
PCR  polymerase chain reaction
PPH  primary pulmonary hypertension
SDE  stress Doppler echocardiography
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Figure 1. Results of the multipoint linkage analysis for the 10 primary pulmonary hypertension families on chromosome 2q31-q33. The thin line (Z) indicates the cumulative lod scores assuming homogeneity.
The thick line indicates the maximum lod score when allowing for heterogeneity (Z(het)max). Indicated above the x-axis are the map positions of the markers. Also indicated is the map position of the bone
morphogenetic protein receptor type 2 gene (BMPR2) locus.
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locus with unknown position), respectively. Posterior prob-
abilities for linkage were calculated using an  of 50%.
Statistics of clinical data. Data in figures and tables are
given as mean values  SD. Linear regression analysis was
used to correlate invasive and noninvasive PASP measure-
ments. Groups were compared by the Mann-Whitney-
Wilcoxon analysis of variance test and (ANOVA). All p
values 0.05 were considered statistically significant.
RESULTS
Clinical assessment of the families of PPH patients. The
pedigrees of 10 PPH patients revealed more than two
potentially informative meioses. Data on these 10 index
patients and their families are presented here as the results
of a prospective study. A total of 130 blood-related mem-
bers (68 male, mean age 31.1  18.4 years; range 6 to 80
years) were assessed clinically and genetically. Twenty-nine
spouses were assessed only genetically. Manifest PPH was
diagnosed invasively or by autopsy in 11 members. This
translates to a total of 21 manifest PPH patients in the 10
families. Three index patients came from families 1490,
4452, and 0965 with confirmed familial disease. In these
families manifest PPH was diagnosed in the respective
index patient and in 11 additional members. The other
seven index patients had a negative family history.
In 109 family members without manifest PPH, SDE was
performed, and in 13 members who complained of symp-
toms RHC was also obtained at rest and during exercise. An
abnormal PASP response to exercise (AR) (from 21.0 4.6
mm Hg to 54.0  9.8 mm Hg) without secondary reasons
(AR members) was found in 46 of the 130 relatives (34.8%)
with a mean age of 33 19 years. In 51 of the 130 members
(36 adults, 15 children 20 years) the PASP values were
normal at rest (21.0  5.0 mm Hg) and during exercise
(37.3  2.3 mm Hg) (NR). In the 13 individuals with
simultaneous RHC (AR members, n  8; NR members,
n 3, secondary pulmonary hypertension n 2), the PASP
values correlated highly to the values obtained by SDE (r 
0.9, standard estimation of error 7.5 mm Hg, p  0.0001).
In seven of the eight AR members diagnosed also by RHC,
mean pulmonary artery pressure exceeded 30 mm Hg (mean
maximal PAP  36  5 mm Hg). Twelve of the 109
relatives were classified as status unknown because second-
ary reasons for pulmonary hypertension could not be ex-
cluded (n  7) or PASP could not be assessed due to
inadequate Doppler signals (n  5).
Clinical assessment of control subjects. Mean PASP of
the 60 control subjects at rest was 20  5 mm Hg and
during exercise 37  6 mm Hg, median 37 mm Hg. In 6 of
the 60 controls (10%), PASP exceeded 40 mm Hg during
exercise and reached a maximum of 53  4 mm Hg. This
exaggerated response to exercise occurred at low workloads
(75 to 100 W) similar to that observed in the AR family
members. The mean maximal PASP value during exercise
in the remaining 54 controls was 36  4 mm Hg. The
number of AR members (members with PASP 40 mm
Hg) was significantly higher in the 10 families with PPH
(46/97 members  47.4%) than in the control group (6/60
 10%, p  0.0001). The group of AR members (n  46),
NR members (n  51), and controls (n  60) did not
significantly differ with respect to gender, age, body weight,
and height. Both AR and NR groups had a similar mean
maximal workload (137  47 W vs. 129  38 W; p 
0.34), mean cardiac output, heart rate (HR), and systemic
blood pressures. The control group had a higher mean
maximal workload (183  50 mm Hg) and higher heart
rates (mean maximal HR 167  16) than did the other
groups (p  0.01).
The BMPR2 mutations and linkage to chromosome
2q33. In 143 of the 159 relatives, genetic analysis was
performed. In 2 of the 10 families a BMPR2 mutation was
identified. Family 4452 showed a Q82X nonsense mutation
in exon 2. This will lead to a truncated protein, missing part
of the ligand-binding domain and all further domains. In
family 3771 an IVS81GT splice mutation at the splice
donor site of intron 8 was found in the index patient with
manifest PPH and in his son with abnormal PASP response
to exercise, but not in the relatives with normal PASP
response to exercise. This mutation will at least disturb the
function of the kinase domain and presumably also cause a
Table 1. Genetic Data of the Individual Families at Various Map Positions
Map Position
Family
965 2135 1893 4452# 3771† 4280 1989 2668 1930 1490
Lod scores in PPH2 region at marker
D2S335 0.06 0.98 1.06 0.62 0.12 0.78 1.02 0.01 0.40 0.29
CHRNA1 3.94 0.98 1.06 0.45 0.10 0.71 1.01 0.03 0.15 0.57
D2S2314 3.71 0.98 1.07 0.44 0.11 0.86 1.02 0.03 0.77 1.56
Lod scores in BMPR2 region
D2S309 2.74 1.09 0.49 1.22 0.15 0.86 0.9 0.09 0.08 0.96
D2S307 3.04 1.06 1.14 1.22 0.16 0.78 1.02 0.09 0.05 1.00
Probability of being PPH2-linked* 99.9% 99% 98% 85%† 53%† 49% 46% 46% 42% 4%
Probability of being BMPR2-linked* 0.1% 1% 2% 15%† 47%† 51% 54% 54% 58% 96%
*Posterior probability calculated under the assumption that 50% of the families are BMPR2-linked and that the remainder are PPH2-linked. †In these families, BMPR2 linkage
was confirmed by mutation analysis.
BMPR2  bone morphogenetic protein receptor type 2 gene; PPH  primary pulmonary hypertension.
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Figure 2. Haplotypes of the PPH2 families: 965, 1893, and 2135. Filled symbols  manifest primary pulmonary hypertension (PPH); half-filled symbols  abnormal pulmonary artery systolic pressure
(PASP) response to exercise (40 mm Hg) (AR). The risk haplotypes are shown in black.
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frame-shift. By linkage analysis we identified only one
additional family (1490) with a significant probability for
being linked to the BMPR2 locus. In the other families,
linkage to the BMPR2 region was excluded, or insignificant
scores were obtained (Fig. 1, Table 1).
The PPH2 locus, a second locus on chromosome 2q31.
In families 965, 2135, and 1893, the posterior probability of
being linked to a more proximal locus on 2q31 (designated
PPH2) was highly significant (p  98%). None of these
families showed a mutation in the BMPR2 gene. In family
965, manifest PPH was diagnosed in six family members.
The haplotypes of the three PPH2-linked families are
shown in Figure 2. The positions of crucial recombinations
were checked by testing additional markers (see Methods).
The highest lod score was found in family 965, the largest
pedigree in this study. We obtained a maximum lod score of
5.22 for this family at a position in-between D2S335 and
CHRNA1. The cumulative lod score for all families
showed a maximum of 5.61 (odds ratio [OR]: 4.1106) at a
position 1 cM proximal to CHRNA1. A comparison of the
haplotypes of the PPH2-linked families showed that the
affected individuals, including the abnormal responders,
share haplotype fragments flanked by the markers D2S335
and D2S2314. The relevant recombinations occurred in
two individuals with manifest PPH and in six family
members with a pathological PASP response during exer-
cise (Table 2).
The cumulative lod score, which represents the evidence
for linkage assuming homogeneity, was compared to the
heterogeneity-adjusted lod score (see Fig. 1). The hypoth-
esis that PPH might be a genetically heterogeneous disorder
was unequivocally supported by our linkage data with an
OR of 2.8·1011 in favor of heterogeneity. This maximum
was obtained with 20% of the families linked to BMPR2
(  0.2).
Comparison of clinical and genetic data. No cases of
apparent nonpenetrance were identified in the three PPH2-
linked families (965, 2135, and 1893), in the single family
with significant linkage to BMPR2 (family 1490), or the
families with a BMPR2 mutation (3771 and 4452). Because
of the uncertain assignment to one of the loci, an evaluation
of penetrance was not possible in the remaining families. In
comparison to our previous study (10), we observed that two
cases of nonpenetrance had progressed to an abnormal
PASP response to exercise. Member IV-22 in family 965
progressed from a maximum PASP during exercise of 38
mm Hg at age 18, to 55 mm Hg at age 20 years. Subject
IV-14 of family 965 progressed from a PASP of 37 mm Hg
to 50 mm Hg two years later. Individual III-1 in family
1490 had progressed from an AR status to manifest PPH
within three years.
In our linkage analysis, every abnormal responder (AR)
was treated as a possible phenocopy in a fully unbiased
manner, yet the results indicate that certain individuals are
more likely to be phenocopies than are others. In family
4452, we observed four such phenocopies. These ARs doTa
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not share the BMPR2 mutation, nor the risk haplotype with
the index patient. In family 965, two additional phenocopies
were identified. Thus, 6 (18%) of the 34 ARs in these six
families were likely to be phenocopies.
DISCUSSION
Locus heterogeneity in PPH. Our results strongly suggest
genetic heterogeneity in PPH with one locus, BMPR2,
mapping to 2q33 and a second locus, PPH2, located on
2q31. According to the haplotypes, the PPH2 locus maps
in-between the markers D2S335 and D2S2314. The lod
scores supporting this location are highly significant.
In a heterogeneity model, the AR status is likely to be a
subclinical phenotype, not only present in carriers of
BMPR2 mutations, but also in PPH2 mutation carriers.
Although we cannot formally exclude PPH2 to be a
modifier gene in an alternative (“two-locus”) model, our
haplotype data do not support this alternative. The data
contribute to a better understanding of the complexity of the
pathogenesis: in some families a BMPR2 mutation is the
primary cause of the disease, whereas in other families a
PPH2 gene defect causes PPH. In other words, a single
mutation causes a person to be at risk for PPH, independent
of the genetic status of the other gene.
In addition, there will be environmental and genetic
factors that trigger the onset of the disease as, for instance,
suggested for appetite-suppressant drugs. An example of a
genetic-modifying factor might be the 5-HTT transporter
(16). Moreover, pulmonary hypertension can also occur as a
component of other diseases, like hemorrhagic hereditary
telangiectasia. Mutations in the gene encoding the activin
receptor line kinase ALK1 have been found in patients with
hemorrhagic hereditary telangiectasia and in relatives suf-
fering from pulmonary hypertension only (17). The ALK1
is a member of the family of TGF-beta–related receptors,
again pointing to the significance of the TGF-beta–related
pathways in the development of PH.
The PPH2 locus and its role in PPH. Because the
number of families reported here is rather small, it is not
possible to give a reliable estimate of the proportion of
families linked to the PPH2 and BMPR2 loci. We cannot
disprove the suggestion that PPH1 (BMPR2) might be the
major PPH locus. Alternatively—in the absence of reliable
data obtained from a large set of families—equal impor-
tance could be attributed to both loci. In any case, we expect
some of the familial and sporadic cases that were reported
BMPR2 mutation-negative to exhibit mutations in the yet
unknown PPH2 gene (5,7). Because both loci lie only 15 to
19 cM apart, many small families will show no recombina-
tion between the two regions. Therefore, it is not possible to
classify small families by means of haplotype analysis. This
might explain why Deng and colleagues (5) failed to find
BMPR2 mutations in several families that showed marker
data consistent—but not conclusive—with linkage to 2q33.
In our own data set, we also found no recombination in a
patient with manifest PPH. This phenomenon, which is a
clear limitation of the study, can be explained by the small
number of families with multiple cases of manifest PPH and
the small number of affected individuals in these families.
Interpretation of high PASP values and the diagnostic
value of SDE. A PASP of 40 mm Hg during supine
bicycle exercise is generally accepted as the upper reference
limit for normal individuals (18,19). This, together with
the data presented here, suggests that the vast majority
of individuals with a pathological PASP are carriers of
BMPR2 or PPH2 mutations. The remaining ARs are
to be classified as phenocopies. Stress Doppler echocar-
diography turned out to be very powerful with respect to
the identification of carriers. We identified no cases of
apparent nonpenetrance. Despite the high sensitivity of the
method, the clinical relevance of a high PASP during
exercise is still a matter of investigation. A yet unknown
proportion of the carriers will never develop manifest PPH
at all.
Candidate genes. The region in-between the markers
D2S335 and D2S2314 is quite large (5 to 6 Mb) and
harbors several interesting genes. A promising candidate is
the ATF2 gene, which maps in the center of the PPH2
region. The ATF2 transcription factor is a member of the
TGF-beta pathway and therefore currently the most likely
candidate for PPH2.
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